[Women Heart Disease] | Apr. 16 (Fri.) 09:30-11:00 Channel 02 | |
---|---|---|
Sex Difference in Cardiovascular Pharmacology | ||
Chairperson(s) | 김명아, 홍경순 | |
Panel | 박상민, 박성미, 변영섭, 윤현주 | |
09:30-09:50 | Basics on Sex Difference in Pharmacokinetics and Pharmacodynamics | 윤성혜 / 서울의대 |
09:50-10:10 | Gender Disparities in Cardiovascular Medications | 김학령 / 서울의대 |
10:10-10:30 | Lipid Lowering Therapies: Does Sex Matter? | 한기훈 / 울산의대 |
10:30-10:50 | Sex Related Issues in the Use of Antiplatelets and Anticoagulants | 김진석 / 고려의대 |
10:50-11:00 | Discussion |
[Myocardial Infarction 1] | Apr. 16 (Fri.) 09:30-11:00 Channel 03 | |
---|---|---|
Controversial Issues for the Treatment of AMI | ||
Chairperson(s) | 오동주, 정명호 | |
Panel | 김원, 박경일, 배장환, 윤영진, 이상록, 한주용 | |
09:30-09:50 | Optimal Choice and Duration of Antiplatelet Therapy in AMI | 정영훈 / 경상의대 |
09:50-10:10 | Timing of PCI for Nonculprit Lesion in STEMI | 최철웅 / 고려의대 |
10:10-10:30 | Intracoronary Imaging-Guided PCI Can Improve Outcomes in AMI? | 이성윤 / 인제의대 |
10:30-10:50 | Lipid Lowering Therapy in AMI: From Guidelines to Implementation | 조경훈 / 전남의대 |
10:50-11:00 | Discussion |
[Cross Specialty: Endocrinology, Nephrology and Cardiology] | Apr. 16 (Fri.) 09:30-11:00 Channel 06 | |
---|---|---|
SGLT2 Inhibitor and SLGT1/2 Inhibitor | ||
Chairperson(s) | 백상홍, 유병수 | |
Panel | 김경진, 박진주, 이상언, 이찬주, 최진오 | |
09:30-09:50 | SGLT2 and SLGT1/2 Inhibitor for Diabetes and Non-diabetes Patients-Endocrinologist’s View | 최성희 / 서울의대 |
09:50-10:05 | CV Outcome Trials of SGLT2 and SLGT1/2 Inhibitor-Cardiologist’s View | 조현재 / 서울의대 |
10:05-10:20 | Renal Outcome Trials of SGLT2 and SLGT1/2 Inhibitor-Nephrologist’s View | 최범순 / 가톨릭의대 |
10:20-10:35 | SGLT2 or SLGT1/2 Inhibitor for CV and Renal Outcomes of Non-diabetic Patients? | 오재원 / 연세의대 |
10:35-11:00 | Discussion |
[Basic Research 1] | Apr. 16 (Fri.) 09:30-11:00 Channel 07 | |
---|---|---|
Recent Issue and Translational Research in COVID-19 | ||
Chairperson(s) | 안영근, 한진 | |
Panel | 권기환, 권유욱, 김용숙, 민필기, 정진옥, 한승환 | |
09:30-09:50 | COVID-19 and Cardiovascular Disease: Myocarditis and RAAS Inhibition | 김인철 / 계명의대 |
09:50-10:10 | Cytokine Storm in COVID-19 | 신의철 / KAIST |
10:10-10:30 | Disease Modeling and Genomics in COVID-19 | 주영석 / KAIST |
10:30-11:00 | Discussion |
[*KSCP-KSC Joint Session] | Apr. 16 (Fri.) 11:10-12:40 Channel 02 | |
---|---|---|
Effect of Physical Activity on Cardiovascular Disease | ||
Chairperson(s) | 최성희, 임상현 | |
11:10-11:35 | Recommendation of Physical Activity in Hypertrophic Cardiomyopathy (HCM); Restriction Is Not Always a Gold Standard! | 김형관 / 서울의대 |
11:30-12:00 | Adapted Excercise-based Cardiac Rehabilitation for Patients with Stroke | 김원석 / 서울의대 |
12:00-12:25 | Physical Activity & Weight Management Through Mobile Healthcare | 김영인 / NOOM |
12:25-12:40 | Discussion |
[Cardiac Pathology] | Apr. 16 (Fri.) 11:10-12:40 Channel 03 | |
---|---|---|
Microscopic / Ultramicroscopic Myocardium | ||
Chairperson(s) | 서정욱, 이상철 | |
Panel | 고지원, 곽재건, 송미경, 윤자경, 최영 | |
11:10-11:30 | Principles, Findings and Application of Eectron Microscopy in Normal and Diseased Heart | 김정선 / 성균관의대 |
11:30-11:50 | Myocardial Ultramicroscopic Changes in Patients with Arrhythmia | 차명진 / 서울의대 |
11:50-12:10 | Myocardial Ischemic Injury under Electron Microscope during Cardiac Surgery | 정준철 / 서울의대 |
12:10-12:40 | Discussion |
[Cross Specialty: Pulmonology & Cardiology] | Apr. 16 (Fri.) 11:10-12:40 Channel 06 | |
---|---|---|
Heart-Lung Interaction: How to Assess Dyspnea with Possible Heart-Lung Disease | ||
Chairperson(s) | 신경철, 김계훈 | |
Panel | 나승원, 박혜윤, 조동혁, 최홍미 | |
11:10-11:30 | Differential Diagnosis of Pulmonary Edema vs Lung Disease: Imaging Perspective | 남주강 / 서울의대 |
11:30-11:50 | How to Interpret PFT in Patients with Heart Disease | 이현 / 한양의대 |
11:50-12:10 | Sleep Apnea: Diagnosis and Treatment | 조재영 / 서울의대 |
12:10-12:30 | Cor Pulmonale : Diagnosis and Treatment | 장성아 / 성균관의대 |
12:30-12:40 | Discussion |
[Basic Research 2] | Apr. 16 (Fri.) 11:10-12:40 Channel 07 | |
---|---|---|
Basic Concepts and Trends of Basic and Translational Cardiovascular Research | ||
Chairperson(s) | 오구택, 최동훈 | |
Panel | 기해진, 김형규, 박훈준, 이상학, 조성우, 홍순준 | |
11:10-11:25 | Vascular Biology | 이승준 / 연세의대 |
11:25-11:40 | Metabolism | 오창명 / GIST |
11:40-11:55 | Stem Cell: iPSC and Disease Modeling | 한정규 / 서울의대 |
11:55-12:10 | Immunology | 윤종찬 / 가톨릭의대 |
12:10-12:40 | Discussion |
[Scientific Session [Samjin]] | Apr. 16 (Fri.) 12:45-13:25 Channel 01 | |
---|---|---|
Customized Treatment for Cardiovascular Patients | ||
Chairperson(s) | 정보영, 한주용 | |
12:45-13:05 | Clopidogrel vs. Aspirin in Stable Patients after PCI | 안성균 / 연세원주의대 |
13:05-13:25 | Role of NOACs with A-Fib | 정중화 / 조선의대 |
[Scientific Session [Viatris]] | Apr. 16 (Fri.) 12:45-13:25 Channel 02 | |
---|---|---|
Evidence Based Strategies: Optimizing an ASCVD Management | ||
Chairperson(s) | 채인호, 안영근 | |
12:45-13:05 | Highlighting Atorvastatin`s CV Protection Evidence in the Last Few Decades | 윤혁준 / 계명의대 |
13:05-13:25 | Amlodipine, Continuous Movement in HTN Treatment in 31 Years | 조덕규 / 연세의대 |
[Scientific Session [Organon]] | Apr. 16 (Fri.) 12:45-13:25 Channel 03 | |
---|---|---|
The Benefit of Ezetimibe/atorvastatin Combination Therapy | ||
Chairperson(s) | 홍명기 | |
12:45-13:15 | Is Combination Therapy Recommended for All High Risk Patients: When and Why Combination Therapy Is Needed? | 조현재 / 서울의대 |
13:15-13:25 | Discussion |
[Scientific Session [Novartis]] | Apr. 16 (Fri.) 12:45-13:25 Channel 04 | |
---|---|---|
ARNI: 1st Choice for Heart Failure Patients to Be Better Life | ||
Chairperson(s) | 전은석, 최동주 | |
12:45-13:05 | Optimal Treatment of Heart Failure According to ACC Update | Gregg C. Fonarow / Ronald Reagan UCLA Medical Center, USA |
13:05-13:25 | ARNI: Maximizing Reverse Cardiac Remodeling Effect in HF | 조재영 / 전남의대 |
[Scientific Session [Boryung]] | Apr. 16 (Fri.) 12:45-13:25 Channel 05 | |
---|---|---|
Current Advance of Management in Cardiovascular Disease | ||
Chairperson(s) | 신동구, 김상현 | |
12:45-13:05 | The Management of Hypertension with Fimasartan in Korea | 신진호 / 한양의대 |
13:05-13:25 | Outcomes after Use of Low-dose NOAC in Patients with AF | 이기홍 / 전남의대 |
[Diamond Session [Amgen]] | Apr. 16 (Fri.) 12:45-13:25 Channel 06 | |
---|---|---|
How to Use PCSK9 Inhibitor for Secondary Prevention After ACS | ||
Chairperson(s) | 박헌식, 허승호 | |
12:45-13:00 | ‘The Earlier, The Better’ Strategy with Evolocumab in ACS Within 1 Year | 김민철 / 전남의대 |
13:00-13:15 | ‘Higher Risk, Higher Benefit’ Strategy with Evolocumab in MI Over 1 Year | 홍순준 / 고려의대 |
13:15-13:25 | Discussion |
[Scientific Session [Pfizer/BMS]] | Apr. 16 (Fri.) 12:45-13:25 Channel 07 | |
---|---|---|
Anticoagulation in Elderly Atrial Fibrillation Patients | ||
Chairperson(s) | 오세일, 한성욱 | |
12:45-13:05 | How to Manage "Age" Risk Factor in AF Patients: Key Findings of Eliquis from Real-world Data | Steven Deitelzweig / University of Queensland, USA |
13:05-13:25 | What Are the Characteristics of AF in Asian Patients? Addressing Issues and Challenges | 김태훈 / 연세의대 |
[Memorial Lecture] | Apr. 16 (Fri.) 13:25-14:25 Channel 06 | |
---|---|---|
Chairperson(s) | 김효수 | |
13:40-13:45 | 故강승호 교수님 회고 | 박진식 / 세종병원 |
13:45-14:25 | Novel Biomedical Roles of Lymphatic Vessels | 고규영 / 기초과학연구원/KAIST |
14:25-14:30 | Discussion |
[Adult Congenital Heart Disease 1] | Apr. 16 (Fri.) 14:30-16:00 Channel 01 | |
---|---|---|
How to Help Rhythm Problem in ACHD | ||
Chairperson(s) | 오용석, 배은정 | |
Panel | 박승정, 윤자경, 윤지홍, 차명진 | |
14:30-14:45 | Current Status of Atrial Arrhythmia in ACHD | 엄재선 / 연세의대 |
14:45-15:00 | Role of Aging in Arrhythmogenesis in ACHD | 박준범 / 이화의대 |
15:00-15:15 | CRT in ACHD | 반지은 / 이화의대 |
15:15-15:30 | Heart Failure Related Rhythm Problem in ACHD | 허준 / 성균관의대 |
15:30-15:45 | Arrhythmia Surgery for Atrial Arrhythmia in ACHD | 박한기 / 연세의대 |
15:45-16:00 | Discussion |
[Myocardial Infarction 2] | Apr. 16 (Fri.) 14:30-16:00 Channel 03 | |
---|---|---|
All about Cardiogenic Shock Following AMI | ||
Chairperson(s) | 권현철, 안영근 | |
Panel | 서석민, 우성일, 유철웅, 이상엽, 이왕수, 이진배 | |
14:30-14:50 | Epidemiology and Clinical Outcomes of Cardiogenic Shock Following AMI | 박진섭 / 부산의대 |
14:50-15:10 | PCI Strategy for AMI with Cardiogenic Shock | 김민철 / 전남의대 |
15:10-15:30 | VA-ECMO for AMI with Cardiogenic Shock: When and How? | 양정훈 / 성균관의대 |
15:30-15:50 | Management for ECMO Complications | 정인석 / 전남의대 |
15:50-16:00 | Discussion |
[Hypertension] | Apr. 16 (Fri.) 14:30-16:00 Channel 04 | |
---|---|---|
Hypertension and Atrial Fibrillation | ||
Chairperson(s) | 김영대, 편욱범 | |
Panel | 김대희, 유승기, 조은주 | |
14:30-14:45 | Hypertension and AF: Pathophysiologic Considerations | 조영진 / 서울의대 |
14:45-15:00 | Blood Pressure Variability and New Onset AF | 권창희 / 건국의대 |
15:00-15:15 | Hypertension and AF: Preventive and Therapeutic Implications | 진은선 / 경희의대 |
15:15-15:30 | Hypertension and AF: Epidemiology in Korea | 이소령 / 서울의대 |
15:30-15:45 | Hypertension and AF: Special Considerations in the Elderly | 최종일 / 고려의대 |
15:45-16:00 | Discussion |
[Guideline Session] | Apr. 16 (Fri.) 14:30-16:00 Channel 06 | |
---|---|---|
What's New in 2020 Guideline Update? | ||
Chairperson(s) | 김영훈, 김효수, 김원호 | |
Panel | 이찬주, 장성아, 최승혁, 한성욱 | |
14:30-14:42 | Adult Congenital Heart Disease | 은영민 / 연세의대 |
14:42-14:54 | Atrial Fibrillation | 이영수 / 대구가톨릭의대 |
14:54-15:06 | Acute Coronary Syndromes(ACS) in Patients Presenting without Persistent ST-Segment Elevation | 이장훈 / 경북의대 |
15:06-15:18 | Sports Cardiology and Exercise in Patients with CVD | 이종영 / 성균관의대 |
15:18-15:30 | Valvular Heart Disease | 정해억 / 가톨릭의대 |
15:30-15:42 | Medical Care in Diabetes | 권혁상 / 가톨릭의대 |
15:42-15:54 | Hypertension | 손일석 / 경희의대 |
15:54-16:00 | Discussion |
[Basic Research Hot Session 1] | Apr. 16 (Fri.) 14:30-16:00 Channel 07 | |
---|---|---|
Cutting-Edge Basic Research in Korea | ||
Chairperson(s) | 권영근, 조현재 | |
Panel | 양한모, 임상현, 조성우 | |
14:30-14:48 | Predicting the Efficiencies and Outcomes of Genome Editing Using Deep Learning | 김형범 / 연세의대 |
14:48-15:06 | MI Vaccine to Prevent Heart Failure | 김병수 / 서울대학교 |
15:06-15:24 | The Role of Myeloid Cells in the Pathogenesis of Atherosclerosis | 오구택 / 이화의대 |
15:24-15:42 | Endothelial Dysfunction: A Strategic Target of Ischemic and Inflammatory Diseases | 권영근 / 연세대학교 |
15:42-16:00 | Discussion |
[Adult Congenital Heart Disease 2] | Apr. 16 (Fri.) 16:10-17:40 Channel 01 | |
---|---|---|
How to Assess ACHD: Imaging Based Appraoch | ||
Chairperson(s) | 박승우, 윤태진 | |
Panel | 김형윤, 조익성, 차슬기, 최은영 | |
16:10-16:25 | How to Assess Complex Congenital Heart Disease: Transthoracic Echocardiography | 김여향 / 경북의대 |
16:25-16:40 | Critical Moment with Tansesophageal Echocardiography | 이승아 / 울산의대 |
16:40-16:55 | Cardiac CT Imaging - Add-on Modality in ACHD Management | 고훈 / 부산의대 |
16:55-17:10 | Right Ventricular Function and More - Cardiac MRI in ACHD | 김영진 / 연세의대 |
17:10-17:25 | Case Based Approach Using Multimodliaty Imaging in ACHD | 박준빈 / 서울의대 |
17:25-17:40 | Discussion |
[Cardiogenic Shock] | Apr. 16 (Fri.) 16:10-17:40 Channel 03 | |
---|---|---|
Basic Approach for Patients with Cardiogenic Shock | ||
Chairperson(s) | 권현철, 최창휴 | |
Panel | 김현중, 안철민, 양정훈, 유철웅, 조현재 | |
16:10-16:25 | Noninvasive and Invasive Monitoring for Critical Care in Cardiogenic Shock | 김인철 / 계명의대 |
16:25-16:40 | Proper Use of Inotropes and Vasopressor by Hemodynamic Status & Clinical Situation | 김민석 / 울산의대 |
16:40-16:55 | Mechanical Circulatory Support in Patient with Cardiogenic Shock: Indication & Weaning | 정재승 / 고려의대 |
16:55-17:10 | From Cardiogenic Shock to LVAD or Heart Transplantation: Best & Worst Case Review | 조양현 / 성균관의대 |
17:10-17:40 | Discussion |
[Epidemiology] | Apr. 16 (Fri.) 16:10-17:40 Channel 05 | |
---|---|---|
Real World Big Data for CVD Epidemiology | ||
Chairperson(s) | Hidehiro Kaneko, Hyeon Chang Kim | |
Panel | Rock Bum Kim, Ki Chul Sung, Il Suk Sohn | |
16:10-16:30 | JMDC Claims Database for CVD Research | Hidehiro Kaneko / The Univ. of Tokyo, Japan |
16:30-16:50 | Japanese Data for Onco-Cardiology Research | Yuichiro Yano / Yokohama City Univ., Japan |
16:50-17:10 | NHI Big Data for CVD Research | Eue-Keun Choi / Seoul National Univ., Korea |
17:10-17:30 | Korean Data for Onco-Cardiology Research | Hyeon Chang Kim / Yonsei Univ., Korea |
17:30-17:40 | Discussion |
[Trials Session] | Apr. 16 (Fri.) 16:10-17:40 Channel 06 | |
---|---|---|
Landmark Trials in 2020 | ||
Chairperson(s) | 김기식, 강덕현, 강현재 | |
Panel | 송영빈, 이승표, 최성훈, 최종일 | |
16:10-16:25 | Landmark Trials in Valvular Heart Disease 2020 | 박재형 / 충남의대 |
16:25-16:40 | Landmark Trials in CAD | 한주용 / 성균관의대 |
16:40-16:55 | Landmark Trials in Lipid and Metabolism | 배장환 / 충북의대 |
16:55-17:10 | Landmark Trials in Arrhythmia | 윤남식 / 전남의대 |
17:10-17:25 | Landmark Trials in Heart Failure | 오재원 / 연세의대 |
17:25-17:40 | Discussion |
[Basic Research Hot Session 2] | Apr. 16 (Fri.) 16:10-17:40 Channel 07 | |
---|---|---|
Cutting-Edge Basic Research in the World | ||
Chairperson(s) | Hyo-Soo Kim, Jin Han | |
Panel | Yoo-Wook Kwon, Yong Sook Kim, Hun-Jun Park, Jung-Kyu Han | |
16:10-16:28 | Single Cell Analysis of Failing Heart | Issei Komuro / Univ. of Tokyo, Japan |
16:28-16:46 | In Vitro Models for Lethal Arrhythmias | Jun K. Yamashita / CiRA, Kyoto Univ., Japan |
16:46-17:04 | Age-related Clonal Hematopoiesis: A New Causal Risk Factor for Cardiovascular Disease | Kenneth Walsh / Boston Univ., USA |
17:04-17:22 | Converting Scar Tissue to Heart Muscle after a Heart Attack | Masaki Ieda / Univ. of Tsukuba, Japan |
17:22-17:40 | Discussion |
[Vascular] | Apr. 17 (Sat.) 09:00-10:30 Channel 03 | |
---|---|---|
Clonal Hematopoiesis of Indeterminate Potential (CHIP) as Emerging Risk Factor in Chronic Cardiovascular Disease | ||
Chairperson(s) | Jong-Won Ha, Ki Chul Sung | |
Panel | Jin Sun Park, Chan Joo Lee, Hae-Young Lee, Jae Hyuk Choi | |
09:00-09:20 | What Is Clonal Hematopoiesis of Indeterminate Potential (CHIP)? | Siddhartha Jaiswal / Stanford Univ., USA |
09:20-09:40 | CHIP, A Common Risk Factor for Cardiology and Oncology | Youngil Koh / Seoul National Univ., Korea |
09:40-10:00 | CHIP and Atherosclerotic Cardiovascular Disease | Heesun Lee / Seoul National Univ., Korea |
10:00-10:20 | How Will We Use CHIP in Clinical Practice? | Seon Gi Lee / Hallym Univ., Korea |
10:20-10:30 | Discussion |
[Cross Specialty: Critical Care Medicine & Heart Failure] | Apr. 17 (Sat.) 09:00-10:30 Channel 06 | |
---|---|---|
Management of HF in Cardiac ICU | ||
Chairperson(s) | 나성원, 강석민 | |
Panel | 김민석, 양정훈, 정치량, 허진원 | |
09:00-09:20 | Non-invasive Ventilation: CPAP and BiPAP | 김인철 / 계명의대 |
09:20-09:40 | Mechanical Ventilation | 조영재 / 서울의대 |
09:40-10:00 | Lung Ultrasound | 정경수 / 연세의대 |
10:00-10:20 | Postcardiotomy Management | 위진 / 가천의대 |
10:20-10:30 | Discussion |
[Cardio-Oncology] | Apr. 17 (Sat.) 09:00-10:30 Channel 07 | |
---|---|---|
Beyond Cardiology and Oncology | ||
Chairperson(s) | 손일석 | |
Panel | 김학진, 박성미, 윤종찬, 정우백 | |
09:00-09:17 | Clinical Epidemiology for Cardio-oncologists | 조주희 / 성균관대학교 삼성융합의과학원 |
09:17-09:34 | Psycho-oncology for Cardio-oncologists | 김종흔 / 국립암센터 |
09:34-09:51 | Diagnostic Radiology for Cardio-oncologists | 홍유진 / 연세의대 |
09:51-10:08 | Nuclear Medicine for Cardio-oncologists | 조상건 / 전남의대 |
10:08-10:30 | Discussion |
[Imaging] | Apr. 17 (Sat.) 10:40-12:10 Channel 02 | |
---|---|---|
Myocardial Viability Imaging | ||
Chairperson(s) | 송재관, 추기석 | |
Panel | 김성목, 김은경, 팽진철 | |
10:40-11:00 | Role of Myocardial Viability Imaging in Post-STICH Era: Interventionist Perspectives | 안정민 / 울산의대 |
11:00-11:20 | Viability Imaging: ECHO and Cardiologist Perspectives | 조익성 / 연세의대 |
11:20-11:40 | Myocardial Viability: MRI | 박철환 / 연세의대 |
11:40-12:00 | Myocardial Viability: PET/SPECT | 조상건 / 전남의대 |
12:00-12:10 | Discussion |
[Cross Specialty: Cardiac Surgery & Cardiology] | Apr. 17 (Sat.) 10:40-12:10 Channel 06 | |
---|---|---|
Optimize Treatment Outcomes of Atrial Fibrillation | ||
Chairperson(s) | 김근직, 온영근 | |
Panel | 김호진, 이소령 | |
10:40-11:00 | Cessation of Anticoagulant and Antiarrhythmics after Successful Maze Operation | 김준범 / 울산의대 |
11:00-11:20 | Role of Intervention after Failed Maze Operation | 김성환 / 가톨릭의대 |
11:20-11:40 | Anticoagulation after Bioprosthetic Mitral Valve Replacement and Maze Operation | 김윤기 / 고려의대 |
11:40-12:00 | Hybrid Option: Thoracoscopic Ablation and RFCA; When and How? | 온영근 / 성균관의대 |
12:00-12:10 | Discussion |
[Scientific Session [Hanmi]] | Apr. 17 (Sat.) 12:15-12:55 Channel 01 | |
---|---|---|
Strategies for Cardiovascular Disease Prevention in Hypertension and Dyslipidemia | ||
Chairperson(s) | 현민수, 장기육 | |
12:15-12:35 | Combination Therapy of Antihypertensive Drugs for Cardiovascular Protection | 최성훈 / 한림의대 |
12:35-12:55 | Why Should We Consider Strongly Rosuvastatin Ezetimibe Combination Therapy? | 한정규 / 서울의대 |
[Scientific Session [Bayer]] | Apr. 17 (Sat.) 12:15-12:55 Channel 02 | |
---|---|---|
Rivaroxaban, Protection Never Rests | ||
Chairperson(s) | 온영근, 고영국 | |
12:15-12:35 | DPI Strategy; New Treatment Paradigm in Poly-vascular Patients | 윤창환 / 서울의대 |
12:35-12:55 | New Perspective in the Management of NVAF Patients with DM | 김인철 / 계명의대 |
[Scientific Session [Daiichisankyo/Daewoong]] | Apr. 17 (Sat.) 12:15-12:55 Channel 03 | |
---|---|---|
Atrial Fibrillation and Hypertension | ||
Chairperson(s) | 최기준, 김남호 | |
12:15-12:35 | How to Manage the Frail Elderly Patient with Atrial Fibrillation | 최의근 / 서울의대 |
12:35-12:55 | Update on Evidence-based Management of High Risk Hypertension Pts (RESOLVE, AMTRAC Study) | 성지동 / 성균관의대 |
[Scientific Session [Boehringer Ingelheim/Lilly]] | Apr. 17 (Sat.) 12:15-12:55 Channel 04 | |
---|---|---|
From Diabetes to Heart, Unleashed Potential of SGLT2 Inhibitor | ||
Chairperson(s) | 김효수, 권현철 | |
12:15-12:35 | Prime Time of SGLT2i Has Begun or Not Yet to Spread? | 김병극 / 연세의대 |
12:35-12:55 | Heart Failure, Further Risk Management for the Patient with Type 2 Diabetes | 윤종찬 / 가톨릭의대 |
[Scientific Session [Amgen]] | Apr. 17 (Sat.) 12:15-12:55 Channel 05 | |
---|---|---|
The PCSK9 Inhibitor: For Whom, When and Why? | ||
Chairperson(s) | 배장호, 이상학 | |
12:15-12:30 | My Clinical Experiences of Evolocumab in Recent ACS | 안종화 / 경상의대 |
12:30-12:45 | PCSK9 Inhibitor: New Hope for FH Treatment | 성지동 / 성균관의대 |
12:45-12:55 | Discussion |
[Diamond Session [Viatris]] | Apr. 17 (Sat.) 12:15-12:55 Channel 06 | |
---|---|---|
Impact of Statins on CV Outcomes: It`s a Matter of Life and Death | ||
Chairperson(s) | 강석민, 양동헌 | |
12:15-12:35 | Are You Up-To-Date on the Treatment of Dyslipidemia?: The Cardiovascular Benefit of Maximum Tolerated Intensity Statin | 이장훈 / 경북의대 |
12:35-12:55 | Looking Beyond LDL-C Lowering to Reduce Cardiovascular Events | 이종영 / 성균관의대 |
[Scientific Session [Celltrion Pharm/Dong-A ST]] | Apr. 17 (Sat.) 12:15-12:55 Channel 07 | |
---|---|---|
BP Control in Uncontrolled Hypertension | ||
Chairperson(s) | 유병수, 임상현 | |
12:15-12:35 | The Optimal BP Control Strategy in Hypertensive Patients with Comorbidity | 정중화 / 조선의대 |
12:35-12:55 | ARB+CLD Combination Therapy for BP Reduction in RH Patients | 김대희 / 울산의대 |
[Smart Health] | Apr. 17 (Sat.) 13:10-14:40 Channel 01 | |
---|---|---|
State-of-the-Art Machine Learning Techniques in Cardiology | ||
Chairperson(s) | 박승우, 김용진 | |
Panel | 김경희, 심재민, 윤종찬, 전기현, 최하영 | |
13:10-13:30 | Machine Learning in Coronary Intervention | 김중선 / 연세의대 |
13:30-13:50 | Artifical Intelligence in the Diagnosis of Arrhythmia | 오일영 / 서울의대 |
13:50-14:10 | Artifical Intelligence in the Treatment of Hypertension | 이해영 / 서울의대 |
14:10-14:30 | Current Status of Deep Learning in Cardiovascular Imaging | 권지훈 / 울산의대 |
14:30-14:40 | Discussion |
[Healthcare Policy] | Apr. 17 (Sat.) 13:10-14:40 Channel 06 | |
---|---|---|
급성심근경색증 성과향상과 지역불균형 극복을 위한 포괄적 국가관리 추진전략 및 중점과제 | ||
Chairperson(s) | 안태훈, 김효수 | |
Panel | 김록범, 박창범, 배장환, 서존, 정중화 | |
13:10-13:25 | 국가 심뇌혈관질환관리와 지역 불균형 극복 | 김록범 / 경상의대 |
13:25-13:40 | 심뇌혈관질환 예방 및 관리법의 현재와 개선방향(개정의 필요성, 구체적 시행법안 부재의 문제점 중점) | 주호노 / 경희대학교 |
13:40-13:55 | 심뇌혈관질환 성과향상과 지속가능발전을 위한 관리정책(재원마련 중점) | 배장환 / 충북의대 |
13:55-14:10 | 급성 심뇌혈관질환 관리를 위한 응급의료체계 | 박정호 / 서울의대 |
14:10-14:40 | Discussion |
[Cardiac Surgery] | Apr. 17 (Sat.) 14:50-16:20 Channel 01 | |
---|---|---|
Surgery for Tricuspid Regurgitation: Still a Challenge? | ||
Chairperson(s) | 박남희, 홍그루 | |
Panel | 정요천, 주민호 | |
14:50-15:10 | Preoperative Evaluation and Timing of Surgery in Patients with Tricupsid Regurigtation; Still Too Late? | 박성지 / 성균관의대 |
15:10-15:30 | How to Repair the Tircuspid Regurgitation | 이삭 / 연세의대 |
15:30-15:50 | Tricuspid Valve Replacement; A Valid Alternative? | 황호영 / 서울의대 |
15:50-16:10 | Factors Afffecting Early and Long-term Results after Tricuspid Valve Surgery | 정성호 / 울산의대 |
16:10-16:20 | Discussion |
[BESCO*-KSC Joint Session] | Apr. 17 (Sat.) 14:50-16:20 Channel 03 | |
---|---|---|
AI and Hemodynamics | ||
Chairperson(s) | 심은보, 이상형 | |
Panel | 양동현, 최진호 | |
14:50-15:10 | TAVR Valve Leaflet Thrombosis and A Role of CFD Analysis | 이관용 / 가톨릭의대 |
15:10-15:30 | Hemodynamic Characteristics Around a Vulnerable Stenosis | 최우락 / POSTECH |
15:30-15:50 | Deep Learning Models for Predicting Lung Diseases Such as COPD and COVID-19 | 최상헌 / 경북대학교 |
15:50-16:10 | Convoultional Neural Network Method for Classification of Heart Sounds | 유동현 / POSTECH |
16:10-16:20 | Discussion |
[보험위원회 세션] | Apr. 17 (Sat.) 14:50-16:20 Channel 06 | |
---|---|---|
심혈관계 분야 보험관련 현안 및 전략 | ||
Chairperson(s) | 성창현, 채인호 | |
Panel | 고영국, 김원장, 박찬석, 박태호, 배장환, 최성훈 | |
14:50-15:05 | 심초음파 급여 어떻게 진행할까? 학회의 의견 | 심지영 / 연세의대 |
15:05-15:20 | 심초음파 급여 어떻게 진행할까? 지난경험들 | 백영기 / 대한의사협회 |
15:20-15:35 | Discussion | |
15:35-15:50 | TAVI 급여 어떻게 진행할까? 학회의 의견 | 서존 / 순천향의대 |
15:50-16:05 | TAVI 급여 어떻게 진행할까? 진행방향 | 김선우 / 대한의사협회 |
16:05-16:20 | Discussion |